Abeona Therapeutics (ABEO) Return on Capital Employed (2011 - 2026)
Abeona Therapeutics' (ABEO) quarterly Return on Capital Employed came in at 52.11% in Q1 2026, up 2867.0% year-on-year from 1.76% in Q1 2025, and down 14.05% quarter-over-quarter from 45.69% in Q4 2025.
Abeona Therapeutics (ABEO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Abeona Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 52.11% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 2867.0% year-over-year to 52.11% in Q1 2026; TTM through Mar 2026 was 52.11%, a 2867.0% increase from a year earlier, with the FY2025 full-year figure at 66.41%, up 2547.0% from the prior year.
- Return on Capital Employed declined to 52.11% in Q1 2026 per ABEO's latest filing, from 45.69% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 38.44% in Q3 2025 and bottomed at 290.43% in Q3 2022.
- The 5-year median for Return on Capital Employed is 82.48% (2023), against an average of 102.32%.
- Across the five-year window, Return on Capital Employed slumped 23181 bps in 2022 and jumped 19927 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 116.49% in 2022, then increased by 22 bps to 91.31% in 2023, then advanced by 28 bps to 65.4% in 2024, then jumped by 30 bps to 45.69% in 2025, then decreased by 14 bps to 52.11% in 2026.
- Per Business Quant, the three latest ABEO Return on Capital Employed figures stand at 52.11% (Q1 2026), 45.69% (Q4 2025), and 38.44% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Abeona Therapeutics | 107.85 Mn | -60.42 Mn | 6.02 Mn | -52.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.11% |
| Dec 31, 2025 | -45.69% |
| Sep 30, 2025 | -38.44% |
| Jun 30, 2025 | -53.90% |
| Mar 31, 2025 | -80.79% |
| Dec 31, 2024 | -65.40% |
| Sep 30, 2024 | -55.80% |
| Jun 30, 2024 | -64.79% |
| Mar 31, 2024 | -85.92% |
| Dec 31, 2023 | -91.31% |
| Sep 30, 2023 | -91.16% |
| Jun 30, 2023 | -102.05% |
| Mar 31, 2023 | -82.48% |
| Dec 31, 2022 | -116.49% |
| Sep 30, 2022 | -290.43% |
| Jun 30, 2022 | -248.54% |
| Mar 31, 2022 | -174.10% |
| Dec 31, 2021 | -108.66% |
| Sep 30, 2021 | -58.62% |
| Jun 30, 2021 | -52.07% |